SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Aardvark Adventures
DAVE 203.85+0.5%Dec 3 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ~digs who wrote (5171)7/15/2008 11:47:00 PM
From: ~digs  Read Replies (1) of 7944
 
With a dividend yield hovering around 7% and a recent deal with Indian generic drug maker Ranbaxy to delay a copycat version of the world’s best selling drug Lipitor (with $12.7 billion in 2007 sales) for over one year until late 2011, shares of Pfizer (PFE) merit a buy below $18 per share for both income investors and those seeking a safe haven investment during the current bear market.
straightstocks.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News